Free Trial

Cabaletta Bio (CABA) Stock Forecast & Price Target

$11.21
-0.60 (-5.08%)
(As of 04:00 PM ET)

Cabaletta Bio - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 9 Analyst Ratings

Consensus Price Target

$34.33
206.27% Upside
High Forecast$50.00
Average Forecast$34.33
Low Forecast$25.00
TypeCurrent Forecast
5/24/23 to 5/23/24
1 Month Ago
4/24/23 to 4/23/24
3 Months Ago
2/23/23 to 2/23/24
1 Year Ago
5/24/22 to 5/24/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
11 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$34.33$34.33$29.27$14.17
Forecasted Upside206.27% Upside111.03% Upside109.59% Upside63.43% Upside
Get Cabaletta Bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.

CABA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CABA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cabaletta Bio Stock vs. The Competition

TypeCabaletta BioMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.69
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside199.33% Upside823.62% Upside9.52% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/16/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$30.00+136.41%
4/5/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$50.00+196.03%
4/4/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$26.00 ➝ $30.00+80.40%
3/22/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$34.00 ➝ $35.00+98.86%
2/5/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$36.00+63.41%
11/29/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$28.00 ➝ $25.00+66.22%
11/29/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$38.00+177.57%
10/19/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$31.00+130.40%
8/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$34.00+151.11%
3/22/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$12.00+55.24%
3/17/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$10.00+29.03%
2/16/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$14.00 ➝ $18.00+125.28%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 04:55 PM ET.

CABA Frequently Asked Questions

What is Cabaletta Bio's stock forecast and purchase recommendation?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Cabaletta Bio is $34.33, with a high forecast of $50.00 and a low forecast of $25.00. The consensus rating for Cabaletta Bio stock is Buy based on the current 9 buy ratings for CABA. Learn more on CABA's analyst rating history.

Do Wall Street analysts like Cabaletta Bio more than its competitors?

Analysts like Cabaletta Bio more than other "medical" companies. The consensus rating for Cabaletta Bio is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CABA compares to other companies.

Does Cabaletta Bio's stock price have much upside?

According to analysts, Cabaletta Bio's stock has a predicted upside of 118.27% based on their 12-month stock forecasts.

What analysts cover Cabaletta Bio?

Cabaletta Bio has been rated by research analysts at Cantor Fitzgerald, Citigroup, HC Wainwright, and Wells Fargo & Company in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:CABA) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners